Covaxx Initiates P-II Trial of UB-612 Against COVID-19 in Taiwan

 Covaxx Initiates P-II Trial of UB-612 Against COVID-19 in Taiwan

Covaxx Initiates P-II Trial of UB-612 Against COVID-19 in Taiwan

Shots:

  • The Taiwan Ministry of Health and Welfare granted conditional approval to initiate P-II trial of UB-612 in 3,850 subjects including adolescents, adults, and seniors across 11 medical centers and hospitals in Taiwan
  • Additionally, Covaxx collaborated with UNMC to conduct clinical trials in the US, and with Dasa S.A. to conduct P-II/III study and distribute vaccines within Brazil. Covaxx also collaborated with Aurobindo to distribute the vaccine in India and UNICEF
  • COVAXX is in production for the first 100M doses and subsequently over 500M doses in 2021

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: COVAXX

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post